Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011295
Filing Date
2025-08-13
Accepted
2025-08-13 06:59:23
Documents
62
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q epix-20250630x10q.htm   iXBRL 10-Q 1424482
2 EX-31.1 epix-20250630xex31d1.htm EX-31.1 7028
3 EX-31.2 epix-20250630xex31d2.htm EX-31.2 7018
4 EX-32.1 epix-20250630xex32d1.htm EX-32.1 9106
5 GRAPHIC epix-20250630x10q001.jpg GRAPHIC 17235
6 GRAPHIC epix-20250630x10q003.jpg GRAPHIC 38174
7 GRAPHIC epix-20250630x10q004.jpg GRAPHIC 38064
  Complete submission text file 0001558370-25-011295.txt   5101641

Data Files

Seq Description Document Type Size
8 EX-101.SCH epix-20250630.xsd EX-101.SCH 34695
9 EX-101.CAL epix-20250630_cal.xml EX-101.CAL 33009
10 EX-101.DEF epix-20250630_def.xml EX-101.DEF 102540
11 EX-101.LAB epix-20250630_lab.xml EX-101.LAB 284555
12 EX-101.PRE epix-20250630_pre.xml EX-101.PRE 202433
64 EXTRACTED XBRL INSTANCE DOCUMENT epix-20250630x10q_htm.xml XML 715921
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37410 | Film No.: 251208935
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)